SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : OSI Pharmaceuticals (OSIP) - formerly Oncogene -- Ignore unavailable to you. Want to Upgrade?


To: scaram(o)uche who wrote (208)4/1/2004 10:58:01 PM
From: scaram(o)uche  Respond to of 447
 
The results showed cells which were made resistant to the EGFR MAb still responded to gefitinib; conversely cells made resistant to gefitinib did not respond to EGFR MAb.

Message 19970281